Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 19/20 | 0.75 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365 | 0.97 | LTB4R2 (0.80) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL2364 | 0.97 | LTB4R2 (0.80) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL683848 | 0.93 | LTB4R2 (0.69) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL8813917 | 0.90 | LTB4R2 (0.62) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL17946059 | 0.90 | LTB4R2 (0.69) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL8814207 | 0.87 | LTB4R2 (0.66) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL25964113 | 0.87 | LTB4R2 (0.66) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL1639910 | 0.85 | AGTR1 (0.68) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL19342800 | 0.84 | LTB4R2 (0.63) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL12654453 | 0.84 | AGTR1 (0.67) | LTB4R2AGTR1ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | LTB4R2 609/4885AGTR1 3252/4885ABCB11 4659/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | LTB4R2 254/4885AGTR1 8/4885ABCB11 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.